New combo therapy shows promise against tough head and neck cancers
Disease control
Completed
This study tested whether adding the drug setanaxib to the standard immunotherapy pembrolizumab can better shrink tumors in people with advanced head and neck cancer that has returned or spread. 55 adults whose cancer could not be removed by surgery took part. The main goal was t…
Phase: PHASE2 • Sponsor: Calliditas Therapeutics Suisse SA • Aim: Disease control
Last updated May 26, 2026 09:52 UTC